XBiotech Inc (XBIT) - Total Liabilities
Based on the latest financial reports, XBiotech Inc (XBIT) has total liabilities worth $9.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore XBiotech Inc annual equity growth to track the company's year-over-year net asset growth rate.
XBiotech Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how XBiotech Inc's total liabilities have evolved over time, based on quarterly financial data. See XBIT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
XBiotech Inc Competitors by Total Liabilities
The table below lists competitors of XBiotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dutaland Bhd
KLSE:3948
|
Malaysia | RM89.33 Million |
|
Sewoon Medical Co. Ltd
KQ:100700
|
Korea | ₩11.10 Billion |
|
C3 Metals Inc
V:CCCM
|
Canada | CA$1.11 Million |
|
Infragreen Group Ltd
AU:IFN
|
Australia | AU$8.31 Million |
|
Yong Pyong Resort Corp
KO:070960
|
Korea | ₩625.21 Billion |
|
Trans Polonia S.A.
WAR:TRN
|
Poland | zł366.63 Million |
|
24SevenOffice Scandinavia AB
ST:247
|
Sweden | Skr109.79 Million |
|
Kula Gold Ltd
AU:KGD
|
Australia | AU$620.24K |
Liability Composition Analysis (2012–2025)
This chart breaks down XBiotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of XBiotech Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XBiotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XBiotech Inc (2012–2025)
The table below shows the annual total liabilities of XBiotech Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.73 Million | -42.16% |
| 2024-12-31 | $16.82 Million | +116.57% |
| 2023-12-31 | $7.77 Million | +36.27% |
| 2022-12-31 | $5.70 Million | -1.57% |
| 2021-12-31 | $5.79 Million | +13.46% |
| 2020-12-31 | $5.11 Million | -91.66% |
| 2019-12-31 | $61.25 Million | +1978.25% |
| 2018-12-31 | $2.95 Million | +4.88% |
| 2017-12-31 | $2.81 Million | -64.81% |
| 2016-12-31 | $7.99 Million | +26.60% |
| 2015-12-31 | $6.31 Million | +100.44% |
| 2014-12-31 | $3.15 Million | +272.43% |
| 2013-12-31 | $845.00K | -22.97% |
| 2012-12-31 | $1.10 Million | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more